TRATAMIENTO COVID 19

The use of Janus kinase inhibitors in the time of SARS-CoV-2.

J Am Acad Dermatol. 2020 Apr 9. pii: S0190-9622(20)30522-3

https://doi-org.pbidi.unam.mx:2443/10.1016/j.jaad.2020.03.099

https://www-sciencedirect-com.pbidi.unam.mx:2443/science/article/pii/S0190962220305223?via%3Dihub

Effect of High vs Low Doses of Chloroquine Diphosphateas Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

JAMA Netw Open. 2020;3(4.23):e208857.

doi:10.1001/jamanetworkopen.2020.8857

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765270

SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.

Eur Rev Med Pharmacol Sci 2020; 24 (7): 4016-4026

DOI: 10.26355/eurrev_202004_20871

https://www.europeanreview.org/article/20871

COVID-19: lambda interferon against viral load and hyperinflammation.

EMBO Mol Med. 2020 Apr 25.

https://doi.org/10.15252/emmm.202012465

https://www.embopress.org/doi/10.15252/emmm.202012465

Extracorporeal Life Support Organization COVID-19 Interim Guidelines

https://www.google.com/search?client=firefox-b-d&q=The+role+of+extracorporeal+life+support+for+patients+with+COVID-19%3A+Preliminary+results+from+a+statewide+experience.

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.

J Crit Care. 2020 Mar 10. pii: S0883-9441(20)30390-7

https://doi-org.pbidi.unam.mx:2443/10.1016/j.jcrc.2020.03.005

https://www-sciencedirect-com.pbidi.unam.mx:2443/science/article/pii/S0883944120303907?via%3Dihub

Coronaviruses — drug discovery and therapeutic options.

Nat Rev Drug Discov. 2016 May;15(5):327-47.

doi:10.1038/nrd.2015.37

https://www-nature-com.pbidi.unam.mx:2443/articles/nrd.2015.37

COVID-19: combining antiviral and anti-inflammatory treatments.

Lancet Infect Dis. 2020 Apr;20(4):400-402

https://doi-org.pbidi.unam.mx:2443/10.1016/S1473-3099(20)30132-8

https://www-sciencedirect-com.pbidi.unam.mx:2443/science/article/pii/S1473309920301328?via%3Dihub

Current Drugs with Potential for Treatment of COVID-19: A Literature Review.

J Pharm Pharm Sci. 2020;23(1):58-64

https://doi.org/10.18433/jpps31002

https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31002/21552

Covid-19 — The Search for Effective Therapy.

N Engl J Med. 2020 Mar 18.

DOI: 10.1056/NEJMe2005477

https://www-nejm-org.pbidi.unam.mx:2443/doi/full/10.1056/NEJMe2005477?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed

Current status of potential therapeutic candidates for the COVID-19 crisis.

Brain Behav Immun. 2020 Apr 22

https://doi.org/10.1016/j.bbi.2020.04.046

https://reader.elsevier.com/reader/sd/pii/S0889159120305894?token=6871DED5F536AE79B99E8C67C4CBD1A20543E029F4F1F545C7A8266147255506D4477AB6AB7A11D43FAB31EB6F252FF6

Manejo clínico de la infección respiratoria aguda grave presuntamente causada por el nuevo coronavirus (2019-nCoV).

https://apps.who.int/iris/bitstream/handle/10665/330938/WHO-nCoV-Clinical-2020.3-spa.pdf

Manejo clínico de la infección respiratoria aguda grave (IRAG) en caso de sospecha de COVID-19

https://apps.who.int/iris/bitstream/handle/10665/331660/WHO-2019-nCoV-clinical-2020.4-spa.pdf

Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19.

J Clin Med. 2020 Apr 15;9(4)

doi:10.3390/jcm9041131

https://www-ncbi-nlm-nih-gov.pbidi.unam.mx:2443/pubmed/32326602

https://www.google.com/search?client=firefox-b-d&q=Pharmacological+Therapeutics+Targeting+RNA-Dependent+RNA+Polymerase%2C+Proteinase+and+Spike+Protein%3A+From+Mechanistic+Studies+to+Clinical+Trials+for+COVID-19.

Treatment options for COVID-19: The reality and challenges.

J Microbiol Immunol Infect. 2020 Apr 4. pii: S1684-1182(20)30094-3

https://doi-org.pbidi.unam.mx:2443/10.1016/j.jmii.2020.03.034

https://www-sciencedirect-com.pbidi.unam.mx:2443/science/article/pii/S1684118220300943?via%3Dihub

COVID-2019: update on epidemiology, disease spread and management.

Monaldi Arch Chest Dis. 2020 Apr 16;90(1)

https://doi.org/10.4081/monaldi.2020.1292

https://monaldi-archives.org/index.php/macd/article/view/1292/1013

Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options

Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105

https://doi-org.pbidi.unam.mx:2443/10.1093/ofid/ofaa105

https://academic-oup-com.pbidi.unam.mx:2443/ofid/article/7/4/ofaa105/5811022

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.

J Biol Chem. 2020 Apr 13. pii: jbc.RA120.013679.

https://www.jbc.org/cgi/doi/10.1074/jbc.RA120.013679

https://www-jbc-org.pbidi.unam.mx:2443/content/early/2020/04/15/jbc.RA120.013679.long

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.

Antiviral Res. 2020 Apr 10;178:104793.

https://doi-org.pbidi.unam.mx:2443/10.1016/j.antiviral.2020.104793

https://www-sciencedirect-com.pbidi.unam.mx:2443/science/article/pii/S0166354220302072?via%3Dihub

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.

JAMA. 2020 Apr 13

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.6019?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2020.6019

https://jamanetwork-com.pbidi.unam.mx:2443/journals/jama/fullarticle/2764727

Compassionate Use of Remdesivir for Patients with Severe Covid-19.

N Engl J Med. 2020 Apr 10

DOI: 10.1056/NEJMoa2007016

https://www-nejm-org.pbidi.unam.mx:2443/doi/full/10.1056/NEJMoa2007016?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed

Lineamiento para la atención de pacientes por COVID-19.

http://cvoed.imss.gob.mx/lineamiento-para-la-atencion-de-pacientes-por-covid-19/

Comentarios desactivados en TRATAMIENTO COVID 19